<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pharmacy &amp; Pharmacology</journal-id><journal-title-group><journal-title xml:lang="en">Pharmacy &amp; Pharmacology</journal-title><trans-title-group xml:lang="ru"><trans-title>Фармация и фармакология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2307-9266</issn><issn publication-format="electronic">2413-2241</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">111633</article-id><article-id pub-id-type="doi">10.19163/2307-9266-2020-8-1-57-64</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">RETROSPECTIVE ANALYSIS OF ADVERSE DRUG REACTION REPORTING FORMS ASSOCIATED WITH PENICILLIN FAMILY ANTIBIOTICS (PCNE-DRP 9.0) BASED ON DRUG-RELATED APPROACH</article-title><trans-title-group xml:lang="ru"><trans-title>РЕТРОСПЕКТИВНЫЙ АНАЛИЗ КАРТ-ИЗВЕЩЕНИЙ О НЕЖЕЛАТЕЛЬНЫХ РЕАКЦИЯХ АНТИБИОТИКОВ ПЕНИЦИЛЛИНОВОГО РЯДА С ПРИМЕНЕНИЕМ МЕТОДА СИСТЕМЫ ПРОБЛЕМ, СВЯЗАННЫХ С ЛЕКАРСТВЕННЫМИ ПРЕПАРАТАМИ</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title/></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6636-3950</contrib-id><name-alternatives><name xml:lang="en"><surname>Matveev</surname><given-names>Aleksandr V.</given-names></name><name xml:lang="ru"><surname>Матвеев</surname><given-names>Александр Васильевич</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Candidate of Sciences (Medicine), Associate-Professor of Department of Internal medicine No.1 with Clinical Pharmacology, Medical academy n. a. Georgievskiy S. I., ,Vernadsky Crimean Federal University; Executive director of Autonomous non-profit organization “National Scientific Center of Pharmacovigilance”.</p></bio><bio xml:lang="ru"><p>кандидат медицинских наук, доцент кафедры внутренней медицины №1 с курсом клинической фармакологии, Медицинская академия им. С. И. Георгиевского ФГАОУ ВО «КФУ им. В.И. Вернадского»; исполнительный директор АНО «Национальный научный центр фармаконадзора».</p></bio><email>avmcsmu@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7791-6071</contrib-id><name-alternatives><name xml:lang="en"><surname>Krasheninnikov</surname><given-names>Anatoliy E.</given-names></name><name xml:lang="ru"><surname>Крашенинников</surname><given-names>Анатолий Евгеньевич</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Candidate of Sciences (Pharmacy), general director of Autonomous non-profit organization “National Scientific Center of Pharmacovigilance”.</p></bio><bio xml:lang="ru"><p>кандидат фармацевтических наук, генеральный директор АНО «Национальный научный центр фармаконадзора».</p></bio><email>anatoly.krasheninnikov@drugsafety.ru</email></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4012-2523</contrib-id><name-alternatives><name xml:lang="en"><surname>Egorova</surname><given-names>Elena A.</given-names></name><name xml:lang="ru"><surname>Егорова</surname><given-names>Елена Александровна</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Candidate of Sciences (Pharmacy), Associate-Professor of Department of Internal medicine No.1 with Clinical Pharmacology, Medical academy n.a. S. I. Georgievskiy, Vernadsky Crimean Federal University.</p></bio><bio xml:lang="ru"><p>кандидат фармацевтических наук, доцент кафедры внутренней медицины №1 с курсом клинической фармакологии, Медицинская академия им. С.И. Георгиевского ФГАОУ ВО «КФУ им. В. И. Вернадского».</p></bio><email>elena212007@rambler.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Koniaeva</surname><given-names>Elena I.</given-names></name><name xml:lang="ru"><surname>Коняева</surname><given-names>Елена Ивановна</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Candidate of Sciences (Medicine), Associate-Professor of Department of Internal medicine No.1 with Clinical Pharmacology, Medical academy n.a. S. I. Georgievskiy, Vernadsky Crimean Federal University.</p></bio><bio xml:lang="ru"><p>кандидат медицинских наук, доцент кафедры внутренней медицины №1 с курсом клинической фармакологии, Медицинская академия им. С. И. Георгиевского ФГАОУ ВО «КФУ им. В. И. Вернадского».</p></bio><email>konyaeva.simferopol@gmail.com</email><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Autonomous non-profit organization “National Pharmacovigilance Research Center”</institution></aff><aff><institution xml:lang="ru">Автономная некоммерческая организация «Национальный научный центр Фармаконадзора»</institution></aff><aff><institution xml:lang="zh"></institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Medical Academy n. a. S.I. Georgievsky of Vernadskjy CFU</institution></aff><aff><institution xml:lang="ru">Медицинская академия им. С.И. Георгиевского ФГАОУ ВО «КФУ им. В.И. Вернадского»</institution></aff><aff><institution xml:lang="zh"></institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Medical Academy n. a. S.I. Georgievsky of Vernadskjy CFU</institution></aff><aff><institution xml:lang="ru">Медицинская академия им. С.И. Георгиевского ФГАОУ ВО «КФУ им. В.И. Вернадского»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2020-02-15" publication-format="electronic"><day>15</day><month>02</month><year>2020</year></pub-date><volume>8</volume><issue>1</issue><issue-title xml:lang="en">VOL 8, NO1 (2020)</issue-title><issue-title xml:lang="ru">ТОМ 8, №1 (2020)</issue-title><fpage>57</fpage><lpage>64</lpage><history><date date-type="received" iso-8601-date="2022-10-06"><day>06</day><month>10</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2020, Matveev A.V., Krasheninnikov A.E., Egorova E.A., Koniaeva E.I.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2020, Матвеев А.В., Крашенинников А.Е., Егорова Е.А., Коняева Е.И.</copyright-statement><copyright-statement xml:lang="zh">Copyright ©; 2020,</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="en">Matveev A.V., Krasheninnikov A.E., Egorova E.A., Koniaeva E.I.</copyright-holder><copyright-holder xml:lang="ru">Матвеев А.В., Крашенинников А.Е., Егорова Е.А., Коняева Е.И.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://journals.eco-vector.com/2307-9266/article/view/111633">https://journals.eco-vector.com/2307-9266/article/view/111633</self-uri><abstract xml:lang="en"><p>A widespread use of β-lactam antibiotics such as penicillins in practical medicine, and its authorized use in special categories of patients (e.g. children, pregnant and lactating women, the elderly) requires a critical investigation of their safety as well as the obligatory risk assessment before conducting antibacterial pharmacotherapy.</p> <p><bold>The aim of the work</bold> was the conduction of a retrospective study of adverse reactions cases, the identification and analysis of drug-related problems (DRP) associated with the use of penicillin family antibiotics.</p> <p><bold>Materials and methods.</bold> The objects of the study were adverse drug reactions (ADR) associated with the use of penicillin family antibiotics in inpatient and outpatient facilities, as well as the cases of self-treatment, which were recorded in the official ADR reports and then inputted in the regional (Republic of Crimea) database of spontaneous reports called ARCADe (Adverse Reactions in Crimea, Autonomic Database). The covered period is 2009–2018. The analysis of DRP was carried out using the 9.0 version of the qualification system DRP PCNE (Pharmaceutical Care Network Europe Foundation).</p> <p><bold>Results. </bold>The data analysis of ADR<italic> reporting forms</italic> has revealed that Amoxicillin clavulanate and Amoxicillin were the most frequent cause of ADR. A high incidence of penicillins ADR in pediatric patients (from 0 to 18 years) – 142 cases – has been found. The clinical manifestations of reactions included drug hypersensitivity reactions (309 cases), dyspeptic disorders (28 cases) and disorders of the central nervous system (5 cases). The incidence of serious ADR was 113 cases (33% of the total number of ADR in the study), which indicates a rather high risk of developing severe ADR for penicillins, resulted in a significant decrease in the quality of patients’ lives.</p> <p><bold>Conclusion</bold>. The detection of DRP using the PCNE V9.0 approach is a useful and promising tool important to improve the quality of pharmacotherapy and their adherence to treatment. The highest DRP values which were observed for Amoxicillin clavulanate and Amoxicillin, may indicate a high frequency of irrational use of these drugs.</p></abstract><trans-abstract xml:lang="ru"><p>Широкое использование β-лактамных антибиотиков группы пенициллинов в практической медицине, официально допустимое их назначение особым категориям пациентов (дети, беременные и лактирующие женщины, лица пожилого возраста) требует серьезного отношения к изучению безопасности и оценке рисков при проведении антибактериальной фармакотерапии.</p> <p><bold>Целью</bold> работы было ретроспективное изучение случаев нежелательных реакций (НР), а также выявление и анализ проблем, связанных с применением лекарственных препаратов (<italic>Drug-related problems</italic>, DRP) группы пенициллинов.</p> <p><bold>Материалы и методы.</bold> Объектами исследования послужили случаи развития НР при применении группы пенициллинов в стационарных, амбулаторных учреждениях, а также при использовании препаратов в виде самолечения, т.е. карты-извещения о НР, зарегистрированные в региональной (Республика Крым) базе спонтанных сообщений ARCADe (<italic>Adverse Reactions in Crimea, Autonomic Database</italic>) за период 2009–2018 гг. Изучение и анализ DRP, проводились с использованием обновленной версии квалификационной системы DRP PCNE (<italic>Pharmaceutical Care Network Europe Foundation</italic>) V9.0.</p> <p><bold>Результаты </bold>анализа карт-извещений о НР позволили выявить, что препаратами-«лидерами» по частоте развития НР являются амоксициллина клавуланат и амоксициллин. Стоит отметить высокую частоту развития НР на фоне применения пенициллинов у пациентов детского возраста (от 0 до 18 лет) – 142 случая. Клиническими проявлениями НР на антибиотики представленной группы были реакции лекарственной гиперчувствительности (309 случаев), диспепсические расстройства (28 случаев) и нарушения со стороны центральной нервной системы (5 случаев). Частота серьезных НР составила 113 случаев (33% от общего количества НР), что свидетельствует о достаточно высоком риске развития тяжелых НР при применении пенициллинов, сопровождающихся значительным снижением качества жизни пациентов.</p> <p><bold>Заключение. </bold>Выявление DRP при помощи метода PCNE V9.0 является важным и перспективным инструментом, необходимым для повышения качества фармакотерапии пациентов и улучшения их приверженности к лечению. Наиболее высокие показатели значений DRP наблюдались при применении амоксициллина клавуланата и амоксициллина, что свидетельствует о высокой частоте нерационального назначения данных препаратов.</p></trans-abstract><trans-abstract xml:lang="zh"><p/></trans-abstract><kwd-group xml:lang="en"><kwd>penicillins</kwd><kwd>adverse reactions</kwd><kwd>drug-related problems</kwd><kwd>DRP</kwd><kwd>Amoxicillin clavulanate</kwd><kwd>Amoxicillin</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>пенициллины</kwd><kwd>нежелательные реакции</kwd><kwd>проблемы</kwd><kwd>связанные с лекарственными препаратами</kwd><kwd>DRP</kwd><kwd>амоксициллина клавуланат</kwd><kwd>амоксициллин</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Lazareva NB, Rebrova EV, Borisov MS. β-laktamnye antibiotiki:sovremennaya poziciya v pul’monologicheskoj praktike [β-lactam antibiotics: modern position in pulmonary practice]. Practical Pulmonology. 2018;2:76-82. Russian.</mixed-citation><mixed-citation xml:lang="ru">Лазарева Н.Б., Реброва Е.В., Борисов М.С. β-лактамные антибиотики:современная позиция в пульмонологической практике // Практическая пульмонология. 2018. Т. 2. С. 76-82.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Korotkov A. Samyj populyarnyj zashchishchennyj penicillin [The most popular protected penicillin]. Rossijskie apteki. 2011;10:66-9. Russian.</mixed-citation><mixed-citation xml:lang="ru">Коротков А. Самый популярный защищенный пенициллин // Российские аптеки. 2011. Т. 10. С. 66-69.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Kuzmina AV, Polivanov AV, Asetskaya IL, Zyryanov SK. Medicinskie oshibki pri primenenii antibiotikov penicillinovoj gruppy [Medication errors associated with the use of Penicillins]. Clinical microbiology and antimicrobial chemotherapy. 2016;18(2):93-103. Russian.</mixed-citation><mixed-citation xml:lang="ru">Кузьмина А.В., Поливанов В.А., Асецкая И.Л., Зырянов С.К. Медицинские ошибки при применении антибиотиков пенициллиновой группы // Клиническая микробиология и антимикробная химиотерапия. 2016. Т. 18. №2. С. 93-103.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Shenoy ES, Macy E, Rowe T. Evaluation and management of Penicillin allergy. JAMA. 2019;321(2):188-99. DOI:10.1001/jama.2018.19283</mixed-citation><mixed-citation xml:lang="ru">Shenoy E.S., Macy E., Rowe T. Evaluation and management of Penicillin allergy // JAMA. 2019. Vol. 321. N 2. P. 188- 199. DOI:10.1001/jama.2018.19283</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Jung IY, Kim JJ, Lee SJ, Kim J, Seong H, Jeong W, Kim JM. Antibiotic-related adverse drug reactions at a Tertiary Care Hospital in South Korea. Biomed Res Int. 2017. DOI: 10.1155 / 2017/4304973</mixed-citation><mixed-citation xml:lang="ru">Jung I.Y., Kim J.J., Lee S.J., Kim J., Seong H., Jeong W., Kim J.M. Antibiotic-related adverse drug reactions at a Tertiary Care Hospital in South Korea // Biomed Res Int. 2017. DOI: 10.1155/2017/4304973</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Andreyeva IV, Stetsyuk OU. Allergiya na antibiotiki u detej: kto vinovat i chto delat’? [Allergy to antibiotics in children: who is to blame and what to do?] Pediatric Pharmacology. 2013;10(6):42-52. Russian.</mixed-citation><mixed-citation xml:lang="ru">Андреева И.В., Стецюк О.У. Аллергия на антибиотики у детей: кто виноват и что делать? // Педиатрическая фармакология. 2013. T. 10. №6. С. 42-52.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Yakovlev SV. Novaya koncepciya racional’nogo primeneniya antibiotikov v ambulatornoj praktike [New concept of rational use of antibiotics outpatient patient]. Antibiotics and chemotherapy. 2019;64(3-4):48-58. DOI: 10.24411/0235-2990-2019-100017. Russian.</mixed-citation><mixed-citation xml:lang="ru">Яковлев С.В. Новая концепция рационального применения антибиотиков в амбулаторной практике // Антибиотики и химиотерапия. 2019. T. 64. №3-4. С. 48-58. DOI: 10.24411/0235-2990-2019-100017</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">ATC/DDD Index 2019. [cited 2019 Aug 05]. Available from: https://www.whocc.no/atc_ddd_index/.</mixed-citation><mixed-citation xml:lang="ru">ATC/DDD Index 2019. URL: https://www.whocc.no/atc_ddd_index/ (дата обращения: 05.08.2019)</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Federal Law of the Russian Federation No. 61-ФЗ dated April 12, 2010 “On the Circulation of Medicines” [Federal’nyi zakon Rossiiskoi Federatsii №61-FZ ot 12 aprelya 2010 g. «Ob obrashchenii lekarstvennykh sredstv»]. [cited 2019 Sep 10]. Available from: http://www.consultant.ru/document/cons_doc_LAW_99350/. Russian.</mixed-citation><mixed-citation xml:lang="ru">Федеральный закон Российской Федерации №61-ФЗ от 12 апреля 2010 г. «Об обращении лекарственных средств». URL: http://www.consultant.ru/document/cons_doc_LAW_99350/ (дата обращения: 10.09.2019)</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment. [cited 2019 Sep 10]. Available from: https://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf.</mixed-citation><mixed-citation xml:lang="ru">Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment. URL: https://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf (дата обращения: 10.09.2019)</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Binu KM, Nimmy NJ, Varghese GP. A survey of Drug related problems identified by community pharmacy in South India. International Journal of Pharmaceutical, chemical and biological sciences. 2012;2(2):368-74.</mixed-citation><mixed-citation xml:lang="ru">Binu K.M., Nimmy N.J., Varghese G.P. A survey of Drug related problems identified by community pharmacy in South India // International Journal of Pharmaceutical, chemical and biological sciences. 2012. Vol. 2. N 2. P. 368-374.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Van Mil JW, Westerlund LO, Hersberger KE, SchaeferMA. Drug-relatedproblemclassificationsystems. Ann Pharmacother. 2004;38(5):859-67.</mixed-citation><mixed-citation xml:lang="ru">van Mil J.W., Westerlund L.O., Hersberger K.E., Schaefer M.A. Drug-related problem classification systems // Ann Pharmacother. 2004. Vol. 38. N 5. P. 859-867.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Matveev AV, Krasheninnikov АЕ, Egorova ЕА, Konyaeva ЕI. Primenenie sistemy problem, svyazannyh s lekarstvennymi preparatami (drug-related problems), na primere gruppy nesteroidnyh protivovospalitel’nyh sredstv [Application of drug-related problems approach to analysis of nonsteroidal anti-inflammatory drugs’ safety]. Pharmacy &amp; Pharmacology. 2019;7(4): 215-223. DOI: 10.19163/2307-9266-2019-7-4-215-223. Russian.</mixed-citation><mixed-citation xml:lang="ru">Матвеев А.В., Крашенинников А.Е., Егорова Е.А., Коняева Е.И. Применение системы проблем, связанных с лекарственными препаратами (drug-related problems), на примере группы нестероидных противовоспалительных средств // Фармация и фармакология. 2019. T. 7. №4. С. 215-223. DOI: 10.19163/2307-9266-2019-7-4-215-223</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Blix HS, Viktil KK, Moger TA, Reikvam AR. Risk of drug‐related problems for various antibiotics in hospital: assessment by use of a novel method. Pharmacoepidemiology and Drug Safety. 2008;17(8):834-41. DOI: 10.1002/pds.1595</mixed-citation><mixed-citation xml:lang="ru">Blix H.S., Viktil K.K., Moger T.A., Reikvam A.R. Risk of drug-related problems for various antibiotics in hospital: assessment by use of a novel method // Pharmacoepidemiology and Drug Safety. 2008. Vol. 17. N 8. P. 834-841. DOI: 10.1002/pds.1595</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Paulino EI, Bouvy ML, Gastelurrutia MA, Mara Guerreiro, Henk Buurma. Drug related problems identified by European community pharmacists in patients discharged from hospital. Pharm World Sci. 2004;26:353–6.</mixed-citation><mixed-citation xml:lang="ru">Paulino E.I., Bouvy M.L., Gastelurrutia M.A., Mara Guerreiro, Henk Buurma. Drug related problems identified by European community pharmacists in patients discharged from hospital // Pharm World Sci. 2004. Vol. 26. P. 353-356.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Abunahlah N, Elawaisi A, Velibeyoglu FM. Drug related problems identified by clinical pharmacist at the Internal Medicine Ward in Turkey. Int J Clin Pharm. 2018;40:360–7. DOI: 10.1007/s11096-017-0585-5</mixed-citation><mixed-citation xml:lang="ru">Abunahlah N., Elawaisi A., Velibeyoglu F.M. Drug related problems identified by clinical pharmacist at the Internal Medicine Ward in Turkey // Int J Clin Pharm. 2018. Vol. 40. P. 360-367. DOI: 10.1007/s11096-017-0585-5</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Adusumilli PK, Adepu R. Drug related problems: an over view of various classification systems. Asian J Pharm Clin Res. 2014;7:7–10.</mixed-citation><mixed-citation xml:lang="ru">Adusumilli P.K., Adepu R. Drug related problems: an over view of various classification systems // Asian J Pharm Clin Res. 2014. Vol. 7. P. 7-10.</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Abdela OA, Bhagavathula AS, Getachew H. Risk factors for developing drug‐related problems in patients with cardiovascular diseases attending Gondar University Hospital, Ethiopia. J Pharm Bioallied Sci. 2016;8(4):289–95.</mixed-citation><mixed-citation xml:lang="ru">Abdela O.A., Bhagavathula A.S., Getachew H. Risk factors for developing drug-related problems in patients with cardiovascular diseases attending Gondar University Hospital, Ethiopia // J Pharm Bioallied Sci. 2016. Vol. 8. N4. P. 289-295.</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Al‐Azzam SI, Alzoubi KH, Abu Ruz S, Alefan Q. Drug‐related problems in a sample of outpatients with chronic diseases: a cross‐sectional study from Jordan. Ther Clin Risk Manag. 2016;12:233–9. DOI: 10.2147/TCRM.S98165</mixed-citation><mixed-citation xml:lang="ru">Al-Azzam S.I., Alzoubi K.H., AbuRuz S., Alefan Q. Drugrelated problems in a sample of outpatients with chronic diseases: a cross-sectional study from Jordan // Ther Clin Risk Manag. 2016. Vol. 12. P. 233-239. DOI: 10.2147/TCRM.S98165</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">Pharmaceutical Care Network Europe. PCNE DRP classification V 9.0 [cited 2019 Sep 08]. Available from: https://www.pcne.org/working-groups/2/drug-related-problem-classification.</mixed-citation><mixed-citation xml:lang="ru">Pharmaceutical Care Network Europe. PCNE DRP classification now 8.02.2017. URL: https://www.pcne.org/news/68/pcne-drp-classification-now-802 (дата обращения: 08.09.2019)</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Eichenberger PM. Classification of drug-related problems with new prescriptions using a modified PCNE classification system. Pharmacy World &amp; Science. 2010;3(32):362–72.</mixed-citation><mixed-citation xml:lang="ru">Eichenberger P.M. Classification of drug-related problems with new prescriptions using a modified PCNE classification system // Pharmacy World &amp; Science. 2010. Vol. 3. N 32. P. 362-372.</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">Kozlov RS, Golub AV. Strategiya ispol’zovaniya antimikrobnyh preparatov kak popytka renessansa antibiotikov [Antimicrobial Stewardship as a Renascence of the ‘Golden Age’ of Antibiotics]. Clinical Microbiology and antimicrobial chemotherapy. 2011;13:322-34. Russian.</mixed-citation><mixed-citation xml:lang="ru">Козлов Р.С., Голуб А.В. Стратегия использования антимикробных препаратов как попытка ренессанса антибиотиков // Клиническая микробиология и антимикробная химиотерапия. 2011. №13. С. 322-334.</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">Zhuravleva MV, Romanov BK, Gorodetskaya GI, Muslimova OV, Krysanova VS, Demchenkova EYu. Aktual’nye voprosy bezopasnosti lekarstvennyh sredstv, vozmozhnosti sovershenstvovaniya sistemy farmakonadzora [Topical issues of drug safety, possibilities of improving of pharmacovigilance]. Safety and Risk of Pharmacotherapy. 2019;7(3):109–19. Russian.</mixed-citation><mixed-citation xml:lang="ru">Журавлева М.В., Романов Б.К., Городецкая Г.И. Актуальные вопросы безопасности лекарственных средств, возможности совершенствования системы фармаконадзора // Безопасность и риск фармакотерапии. 2019. T. 7. №3. С. 109-119. DOI: 10.30895/2312-7821-2019-7-3-109-119</mixed-citation></citation-alternatives></ref></ref-list></back></article>
